𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C

✍ Scribed by Bart J. Veldt; Hans J.J. van der Vliet; B. Mary E. von Blomberg; Hans van Vlierberghe; Guido Gerken; Nobusuke Nishi; Kunihiko Hayashi; Rik J. Scheper; Robert J. de Knegt; Alfons J.M. van den Eertwegh; Harry L.A. Janssen; Carin M.J. van Nieuwkerk

Book ID
117982904
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
170 KB
Volume
47
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Interferon-α and zidovudine combination
Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trial
✍ Harry L. A. Janssen; Luuk Berk; Rudolf A. Heijtink; Fiebo J. W. Ten Kate; Solko 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Interferon-a therapy leads to HBeAg seroconversion in only one third of patients with chronic hepatitis B. In an attempt to increase the seroconversion rate, we investigated the combination of interferon-a and zidovudine in a subset of patients with presumably low response rates for interferon-a mon

Randomized Controlled Trial of Quinacrin
Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg-Positive Chronic Hepatitis
✍ Henry C. Bodenheimer Jr.; Fenton Schaffner; Salvatore Vernace; Shalom Z. Hirschm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted